Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Bristol-Myers stops...

    Bristol-Myers stops kidney cancer drug test after early success

    Written by Ruby Khatun Khatun Published On 2017-09-11T10:48:28+05:30  |  Updated On 18 Aug 2021 3:21 PM IST

    Bristol-Myers Squibb Co said on Thursday the success of its combination therapy to improve overall survival in kidney cancer patients helped it end the trial well ahead of schedule, despite earlier reporting mixed results on other main goals.


    The company said a combination of Opdivo and Yervoy, its two main drugs, showed superior overall survival rates than a standard-of-care drug in previously untreated patients with advanced or metastatic renal cell carcinoma.


    Last month, Bristol-Myers said the combination treatment had failed to improve progression-free survival in patients but had succeeded in reducing the size of their tumors.


    "We believe the overall survival benefit likely confirms the durability of the signal seen on progression-free survival, leading to a very high likelihood of approval," Leerink Research analyst Seamus Fernandez wrote in a client note.


    The trials to monitor overall survival rates were to run through the second half of 2019, according to Cowen and Co.



    Bristol-Myers said the study was stopped early after the successful results in a planned interim analysis, sending its shares up 4.2 percent to a 52-week high of $62.415.

    Exelixis Inc, which is developing a rival kidney cancer treatment, tumbled 10 percent. But, Bristol-Myers' trial results raised hopes for AstraZeneca Plc's lung cancer therapy that, in July, failed to show progression-free survival.


    Barclays analysts said Bristol-Myers' trial provides perhaps the most explicit evidence to date that progression-free survival may not be the best yardstick to measure the benefit of immunology-oncology drugs.


    That is why, Bernstein analyst Timothy Anderson said, most trials now incorporate overall survival as a primary endpoint.


    Still, Bristol-Myers' Opdivo failed to prolong survival in previously untreated patients with non-small cell lung cancer, the largest cancer market, according to test results earlier this year.


    The failure led to Merck & Co Inc's Keytruda getting a leg up in the key immuno-oncology field and Bristol-Myers' becoming the target of activist investors.


    U.S. health regulators on Wednesday placed a partial hold on three trials testing Opdivo in combination with other medicines for multiple myeloma due to risks seen in similar studies on a rival drug.


    Cowen and Co analysts estimate Opdivo could generate sales of $12.36 billion in 2022, of which renal cell carcinoma would account for about $1.7 billion.


    Renal cell carcinoma is the most common type of kidney cancer in adults, accounting for more than 100,000 deaths worldwide each year, Bristol-Myers estimates.




    (Reporting by Divya Grover in Bengaluru; Editing by Savio D'Souza)



    AstraZenecaBristol-MyersBristol-Myers Squibbkidney cancerkidney cancer drugOpdivorenal cell carcinomasuccesstesttumorsYervoy
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok